Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Dyer M, Rinaldi F, George E, Adler AI.

Lancet Oncol. 2012 Aug;13(8):762-3. No abstract available.

PMID:
23024987
2.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C.

Ann Oncol. 2013 Jul;24(7):1807-12. doi: 10.1093/annonc/mdt136. Epub 2013 Apr 10.

PMID:
23576708
3.

[New treatments for castration-resistant prostate cancer].

Sautois B, Gennigens C.

Rev Med Liege. 2013 Feb;68(2):94-6. French.

PMID:
23469490
4.

Abiraterone and its place in the treatment of metastatic CRPC.

Sartor O, Pal SK.

Nat Rev Clin Oncol. 2013 Jan;10(1):6-8. doi: 10.1038/nrclinonc.2012.202. Epub 2012 Nov 13.

PMID:
23149889
5.

NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Jilani A, George E, Adler AI.

Lancet Oncol. 2012 Jun;13(6):573-4. No abstract available.

PMID:
22833888
6.

[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].

Ouzaid I, Ravery V, Pouessel D, Culine S.

Prog Urol. 2013 Jan;23(1):1-7. doi: 10.1016/j.purol.2012.07.007. Epub 2012 Aug 13. Review. French.

PMID:
23287477
7.

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.

Sartor O, Michels RM, Massard C, de Bono JS.

Oncologist. 2011;16(11):1487-97. doi: 10.1634/theoncologist.2010-0412. Epub 2011 Nov 2. Review.

8.

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care..

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.

PMID:
23587782
9.

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.

Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064. Epub 2015 Aug 26.

PMID:
26306637
10.

[Second line therapy for castration-resistant prostate cancer (CRPC)].

Molitor B, Börgermann C.

Urologe A. 2012 Mar;51(3):357-62. doi: 10.1007/s00120-011-2758-5. Review. German.

PMID:
22113549
11.

A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.

Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.

Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070. Epub 2015 May 15.

PMID:
25981621
12.

Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.

Ansari J, Hussain SA, Alhasso A, Mahmood R, Ansari A, Glaholm J.

Anticancer Agents Med Chem. 2011 Mar;11(3):296-306. Review.

PMID:
21426298
13.
14.

Current clinical trials in castrate-resistant prostate cancer.

Petrylak DP.

Curr Urol Rep. 2011 Jun;12(3):173-9. doi: 10.1007/s11934-011-0187-z. Review.

PMID:
21533748
15.

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ; Abiraterone Global EAP Investigators..

Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.

PMID:
25242048
16.

Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.

Kwak C, Wu TT, Lee HM, Wu HC, Hong SJ, Ou YC, Byun SS, Rhim HY, Kheoh T, Wan Y, Yeh H, Yu MK, Kim CS.

Int J Urol. 2014 Dec;21(12):1239-44. doi: 10.1111/iju.12589. Epub 2014 Aug 6.

17.

Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.

Höfner T, Vallet S, Hadaschik BA, Pahernik S, Duensing S, Hohenfellner M, Jäger D, Grüllich C.

World J Urol. 2015 Jun;33(6):833-9. doi: 10.1007/s00345-014-1375-5. Epub 2014 Aug 12.

PMID:
25113804
18.

Cabazitaxel for castration-resistant prostate cancer.

Froehner M, Wirth MP.

Lancet. 2011 Jan 8;377(9760):121-2; author reply 122-3. doi: 10.1016/S0140-6736(11)60013-5. No abstract available.

PMID:
21215875
19.

Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.

Vasani D, Josephson DY, Carmichael C, Sartor O, Pal SK.

Maturitas. 2011 Oct;70(2):194-6. doi: 10.1016/j.maturitas.2011.07.018. Epub 2011 Aug 9.

20.

Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS.

J Clin Endocrinol Metab. 2012 Feb;97(2):507-16. doi: 10.1210/jc.2011-2189. Epub 2011 Dec 14.

PMID:
22170708

Supplemental Content

Support Center